Why Flecainide Should Be Stopped in Atrial Fibrillation
Flecainide must be discontinued immediately if a patient develops structural heart disease, coronary artery disease, heart failure with reduced ejection fraction (LVEF <35-40%), significant conduction abnormalities (QRS widening >25% from baseline), or ventricular arrhythmias, as continuation poses life-threatening risks of ventricular proarrhythmia and sudden cardiac death. 1, 2
Primary Reasons for Discontinuation
Structural Heart Disease or Coronary Artery Disease
- Flecainide is absolutely contraindicated in patients with coronary artery disease or structural heart disease due to increased mortality risk demonstrated in the landmark CAST trial 1
- The CAST trial showed flecainide increased mortality (5.1% vs 2.3% placebo) and cardiac arrest rates in post-MI patients 2
- The mechanism is ventricular proarrhythmia—specifically monomorphic ventricular tachycardia (not torsades de pointes) 1
- Risk is highest with ventricular conduction delays (QRS >120ms), ventricular scar tissue, or left ventricular dysfunction 1
Heart Failure with Reduced Ejection Fraction
- Flecainide is contraindicated when LVEF falls below 35-40% 1, 3, 2
- The drug has potent negative inotropic effects that can precipitate or worsen heart failure 1, 2
- In clinical trials, 7.7% of patients developed worsened CHF, with onset ranging from hours to months after starting therapy 2
- If heart failure develops during treatment, flecainide must be discontinued or dose-reduced, with optimization of other heart failure therapies 2
Dangerous Conduction Abnormalities
Stop flecainide if any of these ECG changes occur 4, 2:
- QRS widening ≥25% from baseline (sign of potential proarrhythmia requiring immediate discontinuation or dose reduction)
- Second-degree or third-degree AV block develops
- Right bundle branch block with left hemiblock appears
- New bundle branch block emerges
- Sinus node dysfunction (sinus pause, arrest, symptomatic bradycardia)
Conversion to Atrial Flutter with Rapid Ventricular Response
- Flecainide can convert atrial fibrillation to atrial flutter with paradoxically faster 1:1 AV conduction 4, 2, 5
- This occurs because flecainide slows the atrial rate enough to allow 1:1 conduction through the AV node
- This is a medical emergency requiring immediate discontinuation
- Prevention requires concomitant AV nodal blockade (beta-blockers or calcium channel blockers) 4
Chronic Atrial Fibrillation
- Flecainide is NOT recommended for chronic (permanent) atrial fibrillation 2
- Literature review showed 10.5% of chronic AF patients experienced ventricular tachycardia or ventricular fibrillation 2
- The drug is appropriate only for paroxysmal or persistent AF with rhythm control strategy 6
Additional Reasons for Discontinuation
Renal Dysfunction
- Flecainide is renally cleared; acute kidney injury causes drug accumulation and toxicity 7
- Toxicity can manifest as encephalopathy, visual hallucinations, bradycardia, and conduction abnormalities 7
- Dose adjustment or discontinuation required with declining renal function
Adverse Effects Requiring Cessation
Common reasons patients stop flecainide 5, 8:
- Proarrhythmic effects (most common cardiac reason—48% of discontinuations in one study) 8
- Dizziness (15-20%)
- Visual disturbances (blurred vision, difficulty focusing—up to 15%)
- Gastrointestinal complaints
- Bradyarrhythmias
- Suspected ventricular proarrhythmia
Inefficacy
- Approximately 50% of patients show clinical efficacy with long-term use 8
- Insufficient symptom control is a valid reason to discontinue and consider alternative therapies (catheter ablation, different antiarrhythmic) 3, 8
Critical Monitoring Parameters
Before continuing flecainide, verify:
- No structural heart disease (echocardiogram showing normal LVEF and no significant LV hypertrophy)
- No coronary artery disease (stress test in patients >50 years or with cardiac risk factors) 3
- Baseline ECG with QRS <120ms
- Normal renal function
- Concomitant AV nodal blocking agent prescribed 4, 3
During therapy, discontinue if:
- QRS widens ≥25% from baseline 4, 2
- New conduction abnormalities develop
- Heart failure symptoms emerge
- Plasma levels exceed 0.7-1.0 mcg/mL (when measurable) 4, 2
Common Pitfalls to Avoid
- Never continue flecainide if ischemic heart disease is discovered—even if previously well-tolerated 4, 1
- Don't use flecainide without AV nodal blockade—risk of 1:1 atrial flutter conduction 4
- Don't ignore QRS widening—this is your warning sign of impending proarrhythmia 4, 2
- Don't assume "no symptoms" means "safe"—CAST trial patients were asymptomatic yet had increased mortality 2
- Don't use in chronic/permanent AF—only for paroxysmal/persistent AF with rhythm control strategy 2
The most recent and comprehensive guidelines 6 confirm: "Flecainide or propafenone is recommended in patients with AF requiring long-term rhythm control to prevent recurrence and progression of AF, excluding those with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease."